Marco B. Polée

1.4k total citations
10 papers, 162 citations indexed

About

Marco B. Polée is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Marco B. Polée has authored 10 papers receiving a total of 162 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Marco B. Polée's work include Colorectal Cancer Treatments and Studies (4 papers), Renal cell carcinoma treatment (3 papers) and Gastric Cancer Management and Outcomes (3 papers). Marco B. Polée is often cited by papers focused on Colorectal Cancer Treatments and Studies (4 papers), Renal cell carcinoma treatment (3 papers) and Gastric Cancer Management and Outcomes (3 papers). Marco B. Polée collaborates with scholars based in Netherlands, United States and Curacao. Marco B. Polée's co-authors include Maartje Los, Ate van der Gaast, Ronald Hoekstra, Alex Sparreboom, Johanneke E.A. Portielje, Ferry A.L.M. Eskens, Jaap Verweij, Laurens V. Beerepoot, G. Stoter and Aart Beeker and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Marco B. Polée

10 papers receiving 162 citations

Peers

Marco B. Polée
Fiorella Ruatta Italy
Yoshiki Horie Japan
Yang Weizhu China
Gökhan Uçar Türkiye
N. C. Tebbutt Australia
Wafaa Elatre United States
Irene Pecora Italy
Nikhil Pande India
Effie Skrinos Australia
Fabiana Vitiello Italy
Fiorella Ruatta Italy
Marco B. Polée
Citations per year, relative to Marco B. Polée Marco B. Polée (= 1×) peers Fiorella Ruatta

Countries citing papers authored by Marco B. Polée

Since Specialization
Citations

This map shows the geographic impact of Marco B. Polée's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco B. Polée with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco B. Polée more than expected).

Fields of papers citing papers by Marco B. Polée

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco B. Polée. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco B. Polée. The network helps show where Marco B. Polée may publish in the future.

Co-authorship network of co-authors of Marco B. Polée

This figure shows the co-authorship network connecting the top 25 collaborators of Marco B. Polée. A scholar is included among the top collaborators of Marco B. Polée based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marco B. Polée. Marco B. Polée is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Westgeest, Hans M., Maarten J. van der Doelen, Jules L.L.M. Coenen, et al.. (2020). Real-World Outcomes of Radium-223 Dichloride for Metastatic Castration Resistant Prostate Cancer. Future Oncology. 16(19). 1371–1384. 25 indexed citations
2.
Westgeest, Hans M., Ronald de Wit, J.L. Coenen, et al.. (2019). Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands. Clinical Genitourinary Cancer. 17(5). e946–e956. 5 indexed citations
3.
Lougheed, Sinéad M., Paul Hamberg, Marco B. Polée, et al.. (2019). Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus. Cancer Immunology Immunotherapy. 68(5). 787–798. 4 indexed citations
4.
Cirkel, Geert A., Paul Hamberg, Stefan Sleijfer, et al.. (2016). Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer. JAMA Oncology. 3(4). 501–501. 25 indexed citations
5.
6.
Punt, Cornelis J.A., Lieke H. J. Simkens, Johan van Rooijen, et al.. (2016). Randomized phase 3 study of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (mCRC): The SALTO study of the Dutch Colorectal Cancer Group.. Journal of Clinical Oncology. 34(15_suppl). 3640–3640. 2 indexed citations
7.
8.
Kroep, Judith R., Erik van Werkhoven, Marco B. Polée, et al.. (2015). Randomised study of tegafur–uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer — TLC study. Journal of Geriatric Oncology. 6(4). 307–315. 15 indexed citations
9.
Meulendijks, Didier, Laurens V. Beerepoot, Henk Boot, et al.. (2015). Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study. Investigational New Drugs. 34(1). 119–128. 28 indexed citations
10.
Polée, Marco B., Alex Sparreboom, Ferry A.L.M. Eskens, et al.. (2004). A Phase I and Pharmacokinetic Study of Weekly Paclitaxel and Carboplatin in Patients with Metastatic Esophageal Cancer. Clinical Cancer Research. 10(6). 1928–1934. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fiorella Ruatta Breakdown of academic impact, for papers by Yoshiki Horie Breakdown of academic impact, for papers by Yang Weizhu Breakdown of academic impact, for papers by Gökhan Uçar Breakdown of academic impact, for papers by N. C. Tebbutt Breakdown of academic impact, for papers by Wafaa Elatre Breakdown of academic impact, for papers by Irene Pecora Breakdown of academic impact, for papers by Nikhil Pande Breakdown of academic impact, for papers by Effie Skrinos Breakdown of academic impact, for papers by Fabiana Vitiello
Rankless by CCL
2026